Regeneron CEO says fears over Eylea 'greatly exaggerated'

(Reuters) – Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc’s chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter results. Source: Reuters Medical News

Nestle defends itself against baby milk criticism

ZURICH (Reuters) – Nestle defended itself on Thursday against an activist group’s criticism of its baby milk, saying it respects international marketing standards and does not suggest its products are better than breastmilk. Source: Reuters Medical News

Norovirus outbreak worsens though athletes unaffected

PYEONGCHANG (Reuters) – The number of people struck down by a virus causing vomiting and diarrhoea at the Pyeongchang Winter Olympics has more than doubled to 86, though athletes remain unaffected, the Korean Centers for Disease Control and Prevention (KCDC) said. Source: Reuters Medical News

U.S. FDA approves Gilead triple HIV drug, rival files lawsuit

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc’s once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market. Source: Reuters Medical News